8-K: Seres Therapeutics to Sell VOWST Business to Nestl for Up to $335 Million

Seres Therapeutics has agreed to sell its VOWST microbiome therapeutic business to Socit des Produits Nestl S.A. for a total potential consideration of up to $335 million, plus a profit sharing arrangement.

Summary

• Seres Therapeutics has entered into an agreement to sell its VOWST business to Socit des Produits Nestl S.A. for a total potential consideration of up to $335 million.
• The deal includes an upfront cash payment of $100 million, less certain deductions, plus a $60 million prepaid milestone payment.
• Additional cash installment payments of $50 million on January 15, 2025, and $25 million on July 1, 2025, are contingent on Seres' compliance with a Transition Services Agreement.
• Future milestone payments of $125 million and $150 million are tied to achieving worldwide annual net sales of the product at $400 million and $750 million, respectively.
• Seres and Nestl will share 50/50 in the net profit or net loss from the VOWST business in the United States and Canada from the closing date until December 31, 2025.
• Seres will reimburse Nestl for certain costs, including payments under the Memorial Sloan Kettering Cancer Center license agreement, costs related to an ongoing safety study, and 80.1% of rent for the Seres Waltham facility.
• Following the sale, Seres will focus on advancing its other wholly-owned cultivated live biotherapeutic candidates.
• The transaction is subject to approval by Seres stockholders and other customary closing conditions, with a potential termination date of February 6, 2025.

Sentiment

Score: 7

Explanation: The document presents a significant strategic move for Seres, with a positive financial outlook due to the potential for milestone payments and profit sharing. However, the sale of its only commercialized product introduces some uncertainty, resulting in a moderately positive sentiment.

Positives

• The sale provides Seres with significant capital to advance its other pipeline candidates.
• The profit-sharing agreement allows Seres to benefit from the ongoing success of the VOWST product.
• The deal includes a prepayment of a $60 million milestone payment, providing immediate cash flow.
• The agreement includes a cross-license agreement, allowing both companies to utilize certain intellectual property.
• Nestl's investment in Seres stock demonstrates confidence in the company's future.

Negatives

• Seres is selling its only commercialized product, which may impact future revenue streams.
• The deal is subject to stockholder approval, which introduces some uncertainty.
• The profit-sharing agreement is limited to the US and Canada and only until the end of 2025.
• The installment payments are contingent on Seres' compliance with the Transition Services Agreement.
• The deal requires Seres to reimburse Nestl for certain costs during the profit-sharing period.

Risks

• The transaction may not be approved by Seres stockholders.
• The closing of the transaction may be delayed or may not occur at all.
• Seres may not receive the full potential consideration if sales milestones are not met.
• The profit-sharing arrangement may not generate significant revenue for Seres.
• Seres may face challenges in advancing its other pipeline candidates without the VOWST revenue stream.

Future Outlook

Seres expects to focus on advancing SER-155 and other wholly-owned cultivated live biotherapeutic candidates after the sale of the VOWST business.

Management Comments

• The Purchase Agreement has been unanimously approved by the Board.

Industry Context

This transaction reflects the growing interest in microbiome therapeutics and the potential for strategic partnerships and acquisitions in this emerging field. Nestl's acquisition of the VOWST business indicates a commitment to expanding its presence in the therapeutic microbiome space.

Comparison to Industry Standards

• The deal structure, including upfront payments, milestone payments, and profit sharing, is common in the pharmaceutical and biotech industries.
• The valuation of the VOWST business, with a potential total consideration of $335 million, is within the range of similar transactions for commercial-stage assets in the microbiome space.
• The cross-licensing agreement is a common practice in the industry to ensure both parties can continue to operate and develop their respective products.
• The profit-sharing arrangement is a way for Seres to participate in the future success of VOWST, while transferring the operational and commercial risks to Nestl.
• The stock purchase by Nestl is a common way for strategic acquirers to demonstrate confidence in the future of the company.

Stakeholder Impact

• Shareholders will receive value from the sale of the VOWST business and potential future milestone payments.
• Employees involved in the VOWST business may be offered employment with Nestl.
• Customers of VOWST will likely experience a transition in ownership and management of the product.
• Suppliers and partners of the VOWST business will transition to working with Nestl.

Next Steps

• Seres stockholders will vote on the proposed transaction.
• Seres and Nestl will work to satisfy all closing conditions.
• Seres will focus on advancing its other pipeline candidates.
• Seres and Nestl will enter into a Transition Services Agreement to ensure a smooth transfer of the VOWST business.

Key Dates

Keywords

Seres Therapeutics, Nestl, VOWST, microbiome, asset sale, milestone payments, profit sharing, biotherapeutics, MCRB, stock purchase